Curis Q1 net loss $16.1M; cash $120.7M; emavusertib studies on partial clinical hold

CURIS INC

2022-Q1 EPS reported -$0.18 revenue$2,057,000

Net loss $16.1M ($0.18/sh) vs $9.9M in Q1 2021; revenue $2.1M unchanged.
Cash and investments $120.7M; runway into 2024, guidance unchanged.
FDA partial clinical hold on TakeAim Leukemia and Lymphoma studies for emavusertib due to rhabdomyolysis data request.
TakeAim Leukemia data: 40% CR/CRh in spliceosome-mutated AML; 57% ORR in spliceosome-mutated MDS.
CI-8993 (anti-VISTA) dose escalation cleared 0.3mg/kg; now at 0.6mg/kg; RP2D yet to be determined.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.